(VIANEWS) – Cardinal Health (CAH), Lamar Advertising Company (LAMR), Erie Indemnity Company (ERIE) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio as yet. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. Cardinal Health (CAH)
198.77% Payout Ratio
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Earnings Per Share
As for profitability, Cardinal Health has a trailing twelve months EPS of $1.
PE Ratio
Cardinal Health has a trailing twelve months price to earnings ratio of 88.39. Meaning, the purchaser of the share is investing $88.39 for every dollar of annual earnings.
2. Lamar Advertising Company (LAMR)
119.51% Payout Ratio
Founded in 1902, Lamar Advertising (Nasdaq: LAMR) is one of the largest outdoor advertising companies in North America, with over 357,500 displays across the United States and Canada. Lamar offers advertisers a variety of billboard, interstate logo, transit and airport advertising formats, helping both local businesses and national brands reach broad audiences every day. In addition to its more traditional out-of-home inventory, Lamar is proud to offer its customers the largest network of digital billboards in the United States with over 3,600 displays.
Earnings Per Share
As for profitability, Lamar Advertising Company has a trailing twelve months EPS of $4.1.
PE Ratio
Lamar Advertising Company has a trailing twelve months price to earnings ratio of 21.92. Meaning, the purchaser of the share is investing $21.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.79%.
3. Erie Indemnity Company (ERIE)
69.13% Payout Ratio
Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. The company provides sales, underwriting, policy issuance, and renewal services for the policyholders on behalf of the Erie Insurance Exchange. It also offers sales related services, including agent compensation, and sales and advertising support services; and underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. Erie Indemnity Company was incorporated in 1925 and is based in Erie, Pennsylvania.
Earnings Per Share
As for profitability, Erie Indemnity Company has a trailing twelve months EPS of $6.78.
PE Ratio
Erie Indemnity Company has a trailing twelve months price to earnings ratio of 40.8. Meaning, the purchaser of the share is investing $40.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.54%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Erie Indemnity Company’s EBITDA is 4.74.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.7%, now sitting on 3.03B for the twelve trailing months.
Previous days news about Erie Indemnity Company (ERIE)
- According to Zacks on Monday, 4 September, "Some other top-ranked stocks in the insurance space are Erie Indemnity Company (ERIE Quick QuoteERIE – Free Report) , AXIS Capital Holdings Limited (AXS Quick QuoteAXS – Free Report) and Arch Capital Group Ltd. "
- According to Zacks on Wednesday, 6 September, "Some top-ranked stocks from the same space are Erie Indemnity Company (ERIE Quick QuoteERIE – Free Report) and Brown & Brown, Inc. (BRO Quick QuoteBRO – Free Report) ."
4. Bristol (BMY)
59.84% Payout Ratio
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Bristol has a trailing twelve months EPS of $3.76.
PE Ratio
Bristol has a trailing twelve months price to earnings ratio of 15.99. Meaning, the purchaser of the share is investing $15.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.66%.
Previous days news about Bristol (BMY)
- According to Zacks on Monday, 4 September, "Cabozantinib tablets are approved in the United States under the brand name, Cabometyx, for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, and for patients with advanced RCC as a first-line treatment in combination with Bristol Myers’ (BMY Quick QuoteBMY – Free Report) Opdivo."
5. Premier (PINC)
54.42% Payout Ratio
Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and document shredding. The segment is also involved in the provision of the ASCEND Collaborative service for members to receive group purchasing programs, tiers, and prices; SURPASS Collaborative service; STOCKD, an e-commerce platform; and PROVIDEGX program, which identifies supply sources for drugs that are on or may be at risk of being added to the national drug shortage list, or that are vulnerable to pricing volatility, as well as direct sourcing business. The Performance Services segment offers PremierConnect for members to address existing cost and quality imperatives, to manage a value-based care reimbursement model, and support their regulatory reporting framework; performance improvement collaboratives; and consulting and insurance management services, such as creation and management of health benefit programs under Contigo Health brand, as well as health systems and suppliers cost management solutions under Remitra brand. This segment's PremierConnect solutions are organized into six areas, such as Quality & Regulatory, Clinical Surveillance & Safety, Supply Chain & ERP, Operations, Enterprise Analytics, and Clinical Decision Support domains. The company also provides services to other businesses, including food service, schools, and universities. Premier, Inc. was incorporated in 2013 and is headquartered in Charlotte, North Carolina.
Earnings Per Share
As for profitability, Premier has a trailing twelve months EPS of $1.53.
PE Ratio
Premier has a trailing twelve months price to earnings ratio of 14.27. Meaning, the purchaser of the share is investing $14.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.17%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Premier’s EBITDA is 2.15.
Yearly Top and Bottom Value
Premier’s stock is valued at $21.83 at 14:23 EST, way under its 52-week high of $37.53 and above its 52-week low of $21.05.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 1.9% and a drop 9.7% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Aug 30, 2023, the estimated forward annual dividend rate is 0.84 and the estimated forward annual dividend yield is 3.38%.
Previous days news about Premier (PINC)
- According to Zacks on Tuesday, 5 September, "Banking stocks like Premier Financial (PFC Quick QuotePFC – Free Report) and Fifth Third Bancorp (FITB Quick QuoteFITB – Free Report) are worth a look as these too have decent dividend yields.", "Considering the last day’s closing price, Premier Financial’s dividend yield currently stands at 6.4%. "
6. Mid-Southern Bancorp (MSVB)
36.67% Payout Ratio
Mid-Southern Bancorp, Inc. operates as the holding company for Mid-Southern Savings Bank, FSB that provides various banking products and services to individuals and business customers. It accepts various deposit products, including checking, savings, money market, and demand accounts, as well as certificates of deposit and term deposits. The company also offers loans secured by first mortgages on one- to four-family residences, including home equity loans and lines of credit; commercial and multifamily real estate loans; construction loans secured by single-family residences; commercial and multifamily real estate loans; land and lot loans; commercial business loans; consumer loans, including new and used manufactured homes, automobiles and truck, boats, and motorcycles and recreational vehicle loans; loans secured by savings deposits and other personal loans; and unsecured consumer loans. In addition, it holds and manages an investment securities portfolio. The company provides its products and services through its main office in Salem; and through its branch offices located in Mitchell and Orleans, Indiana, as well as through loan production offices located in New Albany, Indiana and Louisville, Kentucky. The company was founded in 1886 and is headquartered in Salem, Indiana.
Earnings Per Share
As for profitability, Mid-Southern Bancorp has a trailing twelve months EPS of $0.6.
PE Ratio
Mid-Southern Bancorp has a trailing twelve months price to earnings ratio of 17.48. Meaning, the purchaser of the share is investing $17.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.76%.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1% and 1%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
1’s EBITDA is 1.
Volatility
1’s last week, last month’s, and last quarter’s current intraday variation average was 1.00%, 1.00%, and 1.00%.
1’s highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).
